{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T18:46:38Z","timestamp":1770835598556,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T00:00:00Z","timestamp":1428969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1016\/j.vaccine.2015.04.015","type":"journal-article","created":{"date-parts":[[2015,4,13]],"date-time":"2015-04-13T04:00:20Z","timestamp":1428897620000},"page":"2629-2636","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":98,"title":["MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine"],"prefix":"10.1016","volume":"33","author":[{"given":"Duccio","family":"Medini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Wassil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.vaccine.2015.04.015_bib0255","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1097\/01.inf.0000147642.85129.05","article-title":"Global epidemiology of meningococcal disease and vaccine efficacy","volume":"23","author":"Pollard","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0260","series-title":"Active bacterial core surveillance report: emerging infections program network; Neisseria meningitidis","author":"Centers for Disease Control and Prevention","year":"2008"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0265","series-title":"Surveillance of invasive bacterial diseases","author":"European Centre for Disease Prevention and Control","year":"2011"},{"issue":"5","key":"10.1016\/j.vaccine.2015.04.015_bib0270","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1586\/erv.11.41","article-title":"Meningococcal serogroup B vaccines: will they live up to expectations?","volume":"10","author":"Zollinger","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0275","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1073\/pnas.1019751108","article-title":"Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination","volume":"108","author":"Budroni","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0280","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1574-6976.2006.00056.x","article-title":"Multilocus sequence typing for global surveillance of meningococcal disease","volume":"31","author":"Brehony","year":"2007","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0285","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.4161\/hv.24129","article-title":"Vaccines against meningococcal serogroup B disease containing outer membrane vesicles (OMV): lessons from past programs and implications for the future","volume":"9","author":"Holst","year":"2013","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0290","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1517\/14712598.2011.585965","article-title":"Recombinant protein meningococcal serogroup B vaccine combined with outer membrane vesicles","volume":"11","author":"Bai","year":"2001","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0295","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S1473-3099(11)70027-5","article-title":"From tailor-made to ready-to-wear meningococcal B vaccines: longitudinal study of a clonal meningococcal B outbreak","volume":"11","author":"Caron","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0300","doi-asserted-by":"crossref","first-page":"4402","DOI":"10.4049\/jimmunol.138.12.4402","article-title":"An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues","volume":"138","author":"Finne","year":"1987","journal-title":"J Immunol"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.04.015_bib0305","doi-asserted-by":"crossref","first-page":"B3","DOI":"10.1016\/j.vaccine.2009.04.071","article-title":"Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis","volume":"27","author":"Holst","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0310","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1586\/erv.11.32","article-title":"A combination recombinant protein and outer membrane vesicle vaccine against serogroup B meningococcal disease","volume":"10","author":"Su","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0315","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1128\/CVI.13.4.486-491.2006","article-title":"The VR2 epitope on the PorA P1.7-2,4 protein is the major target for the immune response elicited by the strain-specific group B meningococcal vaccine MeNZB","volume":"13","author":"Martin","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0320","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/S0264-410X(00)00047-5","article-title":"Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine","volume":"18","author":"Martin","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0325","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1473-3099(09)70324-X","article-title":"Serogroup B meningococcal vaccines: an unfinished story","volume":"10","author":"Sadarangani","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0330","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMra0906357","article-title":"Advances in the development of vaccines against Neisseria meningitidis","volume":"362","author":"Tan","year":"2010","journal-title":"N Engl J Med"},{"issue":"29","key":"10.1016\/j.vaccine.2015.04.015_bib0335","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"issue":"5459","key":"10.1016\/j.vaccine.2015.04.015_bib0340","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.vaccine.2015.04.015_bib0345","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1369-5274(00)00119-3","article-title":"Reverse vaccinology","volume":"3","author":"Rappuoli","year":"2000","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0350","series-title":"Novartis receives positive CHMP opinion for Bexsero\u00ae, a groundbreaking vaccine to help prevent devastating MenB infections, the leading cause of meningitis in Europe","author":"Novartis Vaccines and Diagnostics","year":"2012"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0355","series-title":"FDA approves a second vaccine to prevent serogroup B meningococcal disease","author":"FDA News Release","year":"2015"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0360","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0365","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1084\/jem.129.6.1327","article-title":"Human immunity to the meningococcus. II. Development of natural immunity","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0370","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1084\/jem.129.6.1367","article-title":"Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0375","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1084\/jem.129.6.1385","article-title":"Human immunity to the meningococcus. V. The effect of immunization with meningococcal group C polysaccharide on the carrier state","volume":"129","author":"Gotschlich","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0380","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1073\/pnas.95.6.3140","article-title":"Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms","volume":"95","author":"Maiden","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"10.1016\/j.vaccine.2015.04.015_bib0385","first-page":"845","article-title":"Proposed standardization of Neisseria meningitidis PorA variable-region typing nomenclature","volume":"5","author":"Sacchi","year":"1998","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0390","doi-asserted-by":"crossref","first-page":"19490","DOI":"10.1073\/pnas.1013758107","article-title":"Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines","volume":"107","author":"Donnelly","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9869","key":"10.1016\/j.vaccine.2015.04.015_bib0395","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(12)61961-8","article-title":"Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials","volume":"381","author":"Vesikari","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2015.04.015_bib0400","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1001\/jama.2012.85","article-title":"Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial","volume":"307","author":"Gossger","year":"2012","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.vaccine.2015.04.015_bib0405","doi-asserted-by":"crossref","DOI":"10.4161\/hv.25505","article-title":"Persistence of antibodies in adolescents 18\u201324 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine","volume":"9","author":"Santolaya","year":"2013","journal-title":"Hum Vaccine Immunother"},{"issue":"10","key":"10.1016\/j.vaccine.2015.04.015_bib0410","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1128\/CVI.00202-12","article-title":"Interlaboratory standardization of the sandwich enzyme-linked immunosorbent assay designed for MATS: a rapid, reproducible method for estimating the strain coverage of investigational vaccines","volume":"19","author":"Plikaytis","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0415","series-title":"Poster presented at 27th ICP","article-title":"The use of the Meningococcal Antigen Typing System (MATS) to assess Australian epidemiology and meningococcal strain coverage with multicomponent serogroup B vaccine","author":"Tozer","year":"2013"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0420","series-title":"Poster presented at 18th international pathogenic Neisseria conference (IPNC) meeting","article-title":"MATS based coverage prediction for the 4CMenB vaccine on Neisseria meningitidis B (MenB) Brazilian invasive strains","author":"Lemos","year":"2012"},{"issue":"1","key":"10.1016\/j.vaccine.2015.04.015_bib0425","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.vaccine.2013.03.063","article-title":"Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB)","volume":"32","author":"Bettinger","year":"2013","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.04.015_bib0430","first-page":"103","article-title":"Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic","volume":"63","author":"K\u0159\u00ed\u017eov\u00e1","year":"2014","journal-title":"Epidemiol Mikrobiol Imunol"},{"issue":"5","key":"10.1016\/j.vaccine.2015.04.015_bib0435","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S1473-3099(13)70006-9","article-title":"Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment","volume":"13","author":"Vogel","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0440","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/1471-2180-14-111","article-title":"Diversity of Greek meningococcal serogroup B isolates and estimated coverage of the 4CMenB meningococcal vaccine","volume":"14","author":"Tzanakaki","year":"2014","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0445","series-title":"Poster presented at 18th IPNC","article-title":"Meningococcal antigen typing system (MATS) based coverage prediction for the 4CMenB vaccine in United States","author":"Kim","year":"2012"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0450","series-title":"Poster presented at ESPID","article-title":"Impact vaccination with the Novartis meningococcal serogroup B vaccine 4CMenB (Bexsero\u00ae) on non-serogroup B disease burden in Brazil","author":"Gorla","year":"2014"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0455","series-title":"Princeton University meningococcal disease outbreak","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0460","series-title":"University of California, Santa Barbara meningococcal disease outbreak","author":"Centers for Disease Control and Prevention","year":"2014"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0465","unstructured":"Centers for Disease Control and Prevention. Outbreaks of Serogroup B Meningococcal Disease on University Campuses 2013. Prepared by Patel, Manish. Meningitis and Vaccine Preventable Diseases Branch. Available at: http:\/\/www.cdc.gov\/vaccines\/acip\/meetings\/downloads\/slides-2014-02\/04-mening-patel.pdf."},{"issue":"7","key":"10.1016\/j.vaccine.2015.04.015_bib0470","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.vaccine.2012.12.022","article-title":"Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa?","volume":"31","author":"Hong","year":"2013","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2015.04.015_bib0475","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/erv.11.10","article-title":"Adjuvant properties of meningococcal outer membrane vesicles and the use of adjuvants in Neisseria meningitidis protein vaccines","volume":"10","author":"Sanders","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"10","key":"10.1016\/j.vaccine.2015.04.015_bib0480","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1016\/j.vaccine.2010.12.075","article-title":"Cooperative serum bactericidal activity between human antibodies to meningococcal factor H binding protein and neisserial heparin binding antigen","volume":"29","author":"Vu","year":"2011","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2015.04.015_bib0485","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1128\/IAI.01085-12","article-title":"Transcriptional regulation of the NadA gene in Neisseria meningitidis impacts the prediction of coverage of a multicomponent meningococcal serogroup B vaccine","volume":"81","author":"Fagnocchi","year":"2013","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2015.04.015_bib0490","series-title":"Poster presented at 18th international pathogenic Neisseria conference (IPNC) meeting","author":"Delany","year":"2012"},{"issue":"43","key":"10.1016\/j.vaccine.2015.04.015_bib0495","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1016\/j.vaccine.2013.08.006","article-title":"Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage","volume":"31","author":"Frosi","year":"2013","journal-title":"Vaccine"},{"issue":"Suppl. 2","key":"10.1016\/j.vaccine.2015.04.015_bib0500","doi-asserted-by":"crossref","first-page":"B67","DOI":"10.1016\/j.vaccine.2011.12.126","article-title":"The challenge of post-implementation surveillance for novel meningococcal vaccines","volume":"30","author":"Snape","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004685?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004685?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T11:42:04Z","timestamp":1691581324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15004685"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":50,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S0264410X15004685"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.015","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}